TY - JOUR
T1 - Nanodelivery Systems for Topical Management of Skin Disorders
AU - Cui, Mingyue
AU - Wiraja, Christian
AU - Chew, Sharon Wan Ting
AU - Xu, Chenjie
PY - 2021/2/1
Y1 - 2021/2/1
N2 - Topical drug delivery has inherent advantages over other administration routes. However, the existence of stratum corneum limits the diffusion to small and lipophilic drugs. Fortunately, the advancement of nanotechnology brings along opportunities to address this challenge. Taking the unique features in size and surface chemistry, nanocarriers such as liposomes, polymeric nanoparticles, gold nanoparticles, and framework nucleic acids have been used to bring drugs across the skin barrier to epidermis and dermis layers. This article reviews the development of these formulations and focuses on their applications in the treatment of skin disorders such as acne, skin inflammation, skin infection, and wound healing. Existing hurdles and further developments are also discussed.
AB - Topical drug delivery has inherent advantages over other administration routes. However, the existence of stratum corneum limits the diffusion to small and lipophilic drugs. Fortunately, the advancement of nanotechnology brings along opportunities to address this challenge. Taking the unique features in size and surface chemistry, nanocarriers such as liposomes, polymeric nanoparticles, gold nanoparticles, and framework nucleic acids have been used to bring drugs across the skin barrier to epidermis and dermis layers. This article reviews the development of these formulations and focuses on their applications in the treatment of skin disorders such as acne, skin inflammation, skin infection, and wound healing. Existing hurdles and further developments are also discussed.
KW - nanomedicine
KW - nanoparticles
KW - skin disorder
KW - topical drug delivery
UR - http://www.scopus.com/inward/record.url?scp=85101346194&partnerID=8YFLogxK
UR - https://www.scopus.com/record/pubmetrics.uri?eid=2-s2.0-85101346194&origin=recordpage
U2 - 10.1021/acs.molpharmaceut.0c00154
DO - 10.1021/acs.molpharmaceut.0c00154
M3 - RGC 21 - Publication in refereed journal
C2 - 32470311
SN - 1543-8384
VL - 18
SP - 491
EP - 505
JO - Molecular Pharmaceutics
JF - Molecular Pharmaceutics
IS - 2
ER -